Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

From Genes To Drugs: Targeted Strategies For Melanoma

K. Flaherty, F. S. Hodi, D. Fisher
Published 2012 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
The past decade has revealed that melanoma is comprised of multiple subclasses that can be categorized on the basis of key features, including the clinical stage of disease, the oncogenic molecular 'drivers', the anatomical location or the behaviour of the primary lesion and the expression of specific biomarkers. Although exercises in subclassification are not new in oncology, progress in this area has produced both conceptual and clinical breakthroughs, which, for melanoma, are unprecedented in the modern history of the disease. This Review focuses on these recent striking advances in the strategy of molecularly targeted approaches to the therapy of melanoma in humans.
This paper references
10.1084/jem.20021348
Route of Immunization with Peptide-pulsed Dendritic Cells Controls the Distribution of Memory and Effector T Cells in Lymphoid Tissues and Determines the Pattern of Regional Tumor Control
D. W. Mullins (2003)
Differential expression of the cyclin-dependent kinase inhibitors p16 and p21 in the human melanocytic system.
Y. Wang (1996)
10.1200/JCO.2003.10.005
Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells.
C. Slingluff (2003)
viability
J. Du (2002)
10.1158/1535-7163.MCT-07-0231
AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models
B. Davies (2007)
10.1186/1471-2407-6-85
Evaluation of the kinase domain of c-KIT in canine cutaneous mast cell tumors
J. Webster (2005)
10.1200/JCO.2006.08.3311
Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.
R. Vonderheide (2007)
Phase II trial of 17-allylamino17-demethoxygeldanamycin in patients with metastatic melanoma
Solit (2008)
10.1002/(SICI)1096-9896(199912)189:4<546::AID-PATH487>3.0.CO;2-L
Expression of interleukin‐8 detected by in situ hybridization correlates with worse prognosis in primary cutaneous melanoma
W. Nürnberg (1999)
10.1046/j.1365-2133.1996.d01-1092.x
Expression of platelet‐derived growth factor (PDGF)‐A, PDGF‐B and the PDGF‐alpha receptor, but not the PDGF‐beta receptor, in human malignant melanoma in vivo
R. Barnhill (1996)
10.1038/nature08833
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
G. Hatzivassiliou (2010)
Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine.
J. Banchereau (2001)
The central role of CD4+ T cells in the antitumor immune response
K Hung (1998)
10.1084/JEM.183.1.7
Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity
J. Young (1996)
10.1172/JCI116278
Analysis of T cell receptor variability in tumor-infiltrating lymphocytes from a human regressive melanoma. Evidence for in situ T cell clonal expansion.
L. Ferradini (1993)
10.1038/nature08902
RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF
P. Poulikakos (2010)
10.1038/SJ.JID.5700026
Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma.
V. K. Goel (2006)
10.1200/JCO.2006.24.18_SUPPL.8014
Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma: CALGB 500104.
T. Gajewski (2006)
10.1200/JCO.2003.07.005
Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.
R. Soiffer (2003)
10.1126/science.7652577
A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma
T. Wolfel (1995)
10.1097/CMR.0b013e328307c248
Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma
A. Hauschild (2008)
10.1111/J.0022-202X.2005.23931.X
Recurrent patterns of dual RB and p53 pathway inactivation in melanoma.
G. Yang (2005)
10.2741/1755
The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma.
F. Meier (2005)
A mutated β-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes
Robbins (1996)
10.1021/bi802067u
The crystal structure of BRAF in complex with an organoruthenium inhibitor reveals a mechanism for inhibition of an active form of BRAF kinase.
Peng Xie (2009)
10.1016/S1470-2045(09)70334-1
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.
J. Wolchok (2010)
10.1158/0008-5472.CAN-09-3092
An oncogenic role for ETV1 in melanoma.
J. Jané-Valbuena (2010)
10.1016/S0092-8674(02)00762-6
Bcl2 Regulation by the Melanocyte Master Regulator Mitf Modulates Lineage Survival and Melanoma Cell Viability
G. McGill (2002)
10.1084/JEM.182.3.689
A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma
B. J. Van den Eynde (1995)
implications for normal physiology, malignant transformation, and cancer therapy
Sebti (2005)
10.1084/JEM.188.12.2357
The Central Role of CD4+ T Cells in the Antitumor Immune Response
K. Hung (1998)
10.1126/science.271.5256.1734
Enhancement of Antitumor Immunity by CTLA-4 Blockade
D. Leach (1996)
10.1200/JCO.2007.25.18_SUPPL.3550
A phase I dose escalation trial of a daily oral CDK 4/6 inhibitor PD-0332991
P. O'dwyer (2007)
[Recent findings in ].
(2013)
10.1084/jem.20012100
Rapid Induction of Tumor-specific Type 1 T Helper Cells in Metastatic Melanoma Patients by Vaccination with Mature, Cryopreserved, Peptide-loaded Monocyte-derived Dendritic Cells
B. Schuler-Thurner (2002)
10.1038/ncponc0558
Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy
I. Weinstein (2006)
10.1016/J.CCR.2004.10.014
Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF.
Jinyan Du (2004)
Lineage-specific signaling in melanocytes. C-kit stimulation recruits p300/CBP to microphthalmia
Price (1998)
10.1016/J.YPAT.2012.10.041
RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
A. Mccullough (2013)
10.1073/PNAS.85.11.3875
Characterization of mutagen-activated cellular oncogenes that confer anchorage independence to human fibroblasts and tumorigenicity to NIH 3T3 cells: sequence analysis of an enzymatically amplified mutant HRAS allele.
C. W. Stevens (1988)
10.1002/IJC.2910440413
Presence on a human melanoma of multiple antigens recognized by autologous CTL
B. Den Van Eynde (1989)
10.1084/jem.20040179
CD4+CD25+ T Regulatory Cells Dependent on ICOS Promote Regulation of Effector Cells in the Prediabetic Lesion
A. Herman (2004)
10.1034/j.1600-065X.2002.18806.x
Tumor‐specific shared antigenic peptides recognized by human T cells
P. van der Bruggen (2002)
10.1016/S0952-7915(02)00316-3
NKT cells - conductors of tumor immunity?
M. Smyth (2002)
10.1016/S1471-4906(02)02263-9
New insights into the role of 4-1BB in immune responses: beyond CD8+ T cells.
Byungsuk Kwon (2002)
10.1038/sj.bjc.6603291
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis
T. Eisen (2006)
10.1038/ni0104-7
Dendritic cells: a journey from laboratory to clinic
V. Cerundolo (2004)
10.1046/J.0022-202X.2004.22243.X
Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma.
H. Tsao (2004)
AZD 6244 ( ARRY - 142886 ) vs temozolomide ( TMZ ) in patients ( pts ) with advanced melanoma : an open - label , randomized , multicenter , phase II study
R. Dummer (2008)
10.1038/NM0398-321
Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
S. Rosenberg (1998)
beyond CD8+ T cells
B. Kwon (2002)
10.1158/0008-5472.CAN-08-0235
Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression.
K. S. Smalley (2008)
10.1200/JCO.2007.15.7636
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma.
A. Hauschild (2009)
10.1084/JEM.183.3.1185
A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes
P. Robbins (1996)
10.1038/ng.356
BRafV600E cooperates with Pten silencing to elicit metastatic melanoma
D. Dankort (2009)
10.1158/0008-5472.CAN-03-3433
V599EB-RAF is an Oncogene in Melanocytes
C. Wellbrock (2004)
10.1200/JCO.2005.23.16_SUPPL.3011
A phase 1–2 clinical study of a second generation oral MEK inhibitor, PD 0325901 in patients with advanced cancer
P. LoRusso (2005)
10.1073/PNAS.86.16.6372
Oncogene activation in human benign tumors of the skin (keratoacanthomas): is HRAS involved in differentiation as well as proliferation?
M. Corominas (1989)
10.1016/S1074-7613(00)80406-9
Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells.
Cynthia A Chambers (1997)
10.1158/1078-0432.CCR-07-4068
Detection of Copy Number Alterations in Metastatic Melanoma by a DNA Fluorescence In situ Hybridization Probe Panel and Array Comparative Genomic Hybridization: A Southwest Oncology Group Study (S9431)
S. R. Moore (2008)
10.1200/JCO.2008.26.15_SUPPL.9033
AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: An open-label, randomized, multicenter, phase II study.
R. Dummer (2008)
10.1002/HUMU.20114
Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutations
T. Soussi (2005)
10.1016/J.IT.2004.09.016
DCs and CD40-activated B cells: current and future avenues to cellular cancer immunotherapy.
J. Schultze (2004)
10.1158/0008-5472.CAN-04-1399
Deregulated Akt3 Activity Promotes Development of Malignant Melanoma
J. Stahl (2004)
10.1084/JEM.178.2.489
The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas
V. Brichard (1993)
role in melanoma aggressiveness
Topczewska (2006)
10.1084/JEM.192.7.1027
Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation
G. Freeman (2000)
10.1200/JCO.2007.14.0707
Major response to imatinib mesylate in KIT-mutated melanoma.
F. S. Hodi (2008)
10.1002/ijc.20873
Suppression of oncogenic NRAS by RNA interference induces apoptosis of human melanoma cells
M. Eskandarpour (2005)
Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts.
E. Rofstad (2000)
10.1038/nature10662
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
P. Poulikakos (2011)
10.1007/s10555-005-1583-y
Immunological detection of altered signaling molecules involved in melanoma development
Y. Kawakami (2005)
10.1186/1479-5876-10-246
Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104)
T. Gajewski (2012)
an open-label, randomized, multicenter, phase II study
Dummer (2008)
10.4049/jimmunol.168.11.5483
Immune Responses in 4-1BB (CD137)-Deficient Mice1
B. Kwon (2002)
CALGB 500104
Gajewski (2006)
10.1016/S1055-3207(18)30256-4
Genetically modified tumor cell vaccines.
F. S. Hodi (1998)
10.1097/CJI.0b013e318174a4fe
CTLA-4: Negative Regulator of the Immune Response and a Target for Cancer Therapy
U. Keilholz (2008)
10.1073/PNAS.91.14.6458
Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection.
Y. Kawakami (1994)
10.1200/JCO.2003.10.066
Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.
F. Kabbinavar (2003)
10.1073/PNAS.95.22.13141
Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma.
R. Soiffer (1998)
10.1038/SJ.JID.5700872
Comparison of a treatment strategy combining CCI-779 plus DTIC versus DTIC monotreatment in human melanoma in SCID mice.
C. Thallinger (2007)
10.1038/sj.onc.1206451
PTEN signaling pathways in melanoma
Heng Wu (2003)
10.3410/f.6899956.7634054
Faculty Opinions recommendation of COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.
J. Chernoff (2011)
10.1200/JCO.2008.17.8954
Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment.
L. Fong (2008)
10.1038/nature00766
Mutations of the BRAF gene in human cancer
Helen Davies (2002)
10.1186/1479-5876-3-39
Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin
Kerrington R. Molhoek (2005)
10.1146/ANNUREV.IMMUNOL.23.021704.115839
TNF/TNFR family members in costimulation of T cell responses.
T. Watts (2005)
10.1016/0952-7915(95)80076-X
New tumor antigens recognized by T cells.
B. J. Van den Eynde (1995)
10.1111/j.1755-148X.2009.00599.x
MITF pathway mutations in melanoma
S. Yokoyama (2009)
10.1111/j.1755-148X.2008.00475.x
Dose‐dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation
J. Lutzky (2008)
10.2174/157489208784638767
Anti-CTLA4 monoclonal antibody Ipilimumab in the treatment of metastatic melanoma: recent findings.
M. Lens (2008)
10.1182/BLOOD-2004-10-3944
Enhancing the immunostimulatory function of dendritic cells by transfection with mRNA encoding OX40 ligand.
J. Dannull (2005)
10.1126/science.1194472
Frequent Mutation of BAP1 in Metastasizing Uveal Melanomas
J. Harbour (2010)
10.1126/SCIENCE.1840703
A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.
P. van der Bruggen (1991)
the role of reactive oxygen species
S. Kusmartsev (2003)
10.1073/PNAS.81.12.3670
Mechanism of activation of an N-ras oncogene of SW-1271 human lung carcinoma cells.
Y. Yuasa (1984)
Rapid induction of tumorspecific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells
B Schuler-Thurner (2002)
comparison of prophylaxis and therapy
van Elsas (2001)
10.1084/jem.20042592
Sustained expansion of NKT cells and antigen-specific T cells after injection of α-galactosyl-ceramide loaded mature dendritic cells in cancer patients
D. H. Chang (2005)
10.1111/j.1755-148X.2008.00480.x
Pharmacologic suppression of MITF expression via HDAC inhibitors in the melanocyte lineage
S. Yokoyama (2008)
10.1200/JCO.2010.33.9275
Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification.
J. Guo (2011)
10.1073/pnas.1533209100
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
G. Phan (2003)
10.1158/1535-7163.MCT-08-0140
Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer
S. Shangary (2008)
10.1101/GAD.14.3.301
c-Kit triggers dual phosphorylations, which couple activation and degradation of the essential melanocyte factor Mi.
M. Wu (2000)
a randomised, double-blind, multicentre, phase 2, doseranging study
Wolchok (2010)
Bcl 2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma
G. G. McGill
10.1038/nature03664
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma
Levi A. Garraway (2005)
10.1016/J.MOLMED.2006.07.008
MITF: master regulator of melanocyte development and melanoma oncogene.
C. Levy (2006)
10.1200/JCO.2008.26.15_SUPPL.9006
Axitinib (AG-013736) in patients with metastatic melanoma: A phase II study
J. Fruehauf (2008)
10.1245/s10434-007-9389-5
A Randomized Phase 2 Trial of Bevacizumab with or without Daily Low-Dose Interferon Alfa-2b in Metastatic Malignant Melanoma
Kimberly A. Varker (2007)
Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules.
Z. Shen (1997)
10.1126/SCIENCE.1082015
Role of Raf in Vascular Protection from Distinct Apoptotic Stimuli
Alireza Alavi (2003)
Braf(V600E) cooperates with Pten loss to induce metastatic melanoma
D Dankort (2009)
the active ingredient in bacterial extracts? Nature Med
Krieg (2003)
dendritic cellbased vaccine in the treatment of patients with advanced melanoma
S. Zhang (2007)
10.1002/cncr.21265
CCI‐779 in metastatic melanoma
K. Margolin (2004)
Immunohistochemical determination of vascular endothelial growth factor (VEGF) overexpression in malignant melanoma.
A. Potti (2003)
10.1038/311671A0
A novel transforming gene in a human malignant melanoma cell line
R. Padua (1984)
10.1093/annonc/mdq013
Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.
S. O’Day (2010)
10.1126/SCIENCE.7513904
Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens.
A. Huang (1994)
10.1126/SCIENCE.8153634
A cell cycle regulator potentially involved in genesis of many tumor types.
A. Kamb (1994)
10.1200/JCO.2001.19.2.577
Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival.
S. Ugurel (2001)
10.1158/0008-5472.CAN-06-1538
An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells.
K. S. Smalley (2007)
10.1038/nature10630
A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma
S. Yokoyama (2011)
10.1056/NEJMOA050092
Distinct sets of genetic alterations in melanoma.
J. A. Curtin (2005)
10.1038/nrd2130
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
Scott Wilhelm (2006)
10.1002/cncr.23086
Targeting cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4)
S. O’Day (2007)
10.1093/JNCI/81.24.1893
Model predicting survival in stage I melanoma based on tumor progression.
W. Clark (1989)
10.1038/nm0703-831
CpG motifs: the active ingredient in bacterial extracts?
Arthur M Krieg (2003)
10.1038/sj.onc.1207812
Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference
H. Sumimoto (2004)
10.1038/sj.bjc.6602864
In vitro hypoxia-conditioned colon cancer cell lines derived from HCT116 and HT29 exhibit altered apoptosis susceptibility and a more angiogenic profile in vivo
K. Yao (2005)
10.1200/jco.2004.22.14_suppl.7523
CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium.
K. Margolin (2004)
10.1016/J.EJCA.2004.08.017
Rapamycin inhibits doxorubicin-induced NF-kappaB/Rel nuclear activity and enhances the apoptosis of melanoma cells.
M. Romano (2004)
10.3816/CBC.2009.n.025
A multicenter, single-arm phase II study of pemetrexed plus doxorubicin administered every 21 days in patients with advanced breast cancer.
M. Martín (2009)
10.1038/nature04304
BRAF mutation predicts sensitivity to MEK inhibition
D. Solit (2006)
10.1002/ijc.20865
Effects on proliferation and melanogenesis by inhibition of mutant BRAF and expression of wild‐type INK4A in melanoma cells
Sabrina Rotolo (2005)
10.1084/JEM.180.1.35
A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas
P. Coulie (1994)
10.1016/j.ccr.2010.11.023
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K.
Jessie Villanueva (2010)
10.1634/theoncologist.13-S4-2
The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation.
J. Wolchok (2008)
10.1038/13928
Complete molecular remissions induced by patient-specific vaccination plus granulocyte–monocyte colony-stimulating factor against lymphoma
M. Bendandi (1999)
Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity.
J. Shimizu (1999)
10.1016/J.GDE.2006.12.005
New insight into BRAF mutations in cancer.
N. Dhomen (2007)
10.1038/nm1448
Embryonic and tumorigenic pathways converge via Nodal signaling: role in melanoma aggressiveness
J. Topczewska (2006)
[Phase II study].
H. Niitani (1995)
10.1200/JCO.2010.28.15_SUPPL.8503
Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors.
R. Kefford (2010)
10.1084/JEM.194.4.481
Elucidating the Autoimmune and Antitumor Effector Mechanisms of a Treatment Based on Cytotoxic T Lymphocyte Antigen-4 Blockade in Combination with a B16 Melanoma Vaccine
A. van Elsas (2001)
10.1128/MCB.16.9.4842
HOXB7 constitutively activates basic fibroblast growth factor in melanomas.
A. Carè (1996)
10.1038/nature03890
BRAFE600-associated senescence-like cell cycle arrest of human naevi
C. Michaloglou (2005)
10.1007/s00262-005-0106-6
Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34+ progenitor-derived dendritic cells
J. Fay (2005)
10.1001/jama.2011.746
KIT as a therapeutic target in metastatic melanoma.
R. Carvajal (2011)
10.1128/MCB.9.7.3114
N-ras mutations in human cutaneous melanoma from sun-exposed body sites.
L. J. van 't Veer (1989)
10.1158/1541-7786.MCR-07-2001
BRAF Silencing by Short Hairpin RNA or Chemical Blockade by PLX4032 Leads to Different Responses in Melanoma and Thyroid Carcinoma Cells
E. Sala (2008)
10.1073/pnas.0905833106
MEK1 mutations confer resistance to MEK and B-RAF inhibition
C. Emery (2009)
10.1189/jlb.0103010
Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species
S. Kusmartsev (2003)
10.1002/gcc.20310
Amplification of CDK4 and MDM2 in malignant melanoma
Viswanathan Muthusamy (2006)
10.1158/0008-5472.CAN-06-4152
Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays.
M. Stark (2007)
10.1073/PNAS.90.2.393
Platelet-derived growth factor (PDGF) in oncogenesis: development of a vascular connective tissue stroma in xenotransplanted human melanoma producing PDGF-BB.
K. Forsberg (1993)
10.1038/ncomms1727
Melanoma whole exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance
H. Shi (2012)
10.1200/JCO.2006.06.2984
Somatic activation of KIT in distinct subtypes of melanoma.
J. A. Curtin (2006)
10.1089/CBR.2007.354
Review: dendritic cell-based vaccine in the treatment of patients with advanced melanoma.
S. Zhang (2007)
10.1056/NEJMoa1103782
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
P. Chapman (2011)
10.1200/JCO.2005.23.16_SUPPL.3037
Phase I/II, pharmacokinetic and pharmacodynamic trial of BAY 43–9006 alone in patients with metastatic melanoma
K. Flaherty (2005)
10.1385/IR:27:2-3:341
A translational bridge to cancer immunotherapy
R. Vonderheide (2003)
Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand.
N. Mach (2000)
10.1054/bjoc.2000.1535
Extra c-myc oncogene copies in high risk cutaneous malignant melanoma and melanoma metastases
G. Krähn (2001)
10.1016/j.cell.2009.12.040
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
S. Heidorn (2010)
10.1073/pnas.192461099
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
Yoshiko Iwai (2002)
Suppression of BRAF(V599E) in human melanoma abrogates transformation.
S. Hingorani (2003)
10.1016/j.ccr.2009.02.022
Oncogenic Braf induces melanocyte senescence and melanoma in mice.
N. Dhomen (2009)
10.1084/JEM.180.1.347
Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes
Y. Kawakami (1994)
10.1038/ng.438
Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4
T. Prickett (2009)
10.1016/S0084-392X(09)79192-0
Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi
T. Milman (2010)
New insights into the role of 4 – 1 BB in immune responses : beyond CD 8 + T cells
B. S. Kwon (2002)
10.1158/1078-0432.CCR-08-0575
KIT Gene Mutations and Copy Number in Melanoma Subtypes
C. Beadling (2008)
10.1056/NEJMoa1003466
Improved survival with ipilimumab in patients with metastatic melanoma.
F. S. Hodi (2010)
10.1158/1078-0432.CCR-08-1144
Imatinib Targeting of KIT-Mutant Oncoprotein in Melanoma
X. Jiang (2008)
10.1093/jnci/djn157
Frequent p16-independent inactivation of p14ARF in human melanoma.
D. Freedberg (2008)
10.1038/nature09626
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
R. Nazarian (2010)
10.1158/0008-5472.CAN-06-2554
Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885.
A. J. King (2006)
10.1158/1078-0432.CCR-08-1002
Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Metastatic Melanoma
D. Solit (2008)
is HRAS involved in differentiation as well as proliferation? Proc
M. Corominas (1989)
10.1016/S0264-410X(02)00381-X
Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen.
P. Coulie (2002)
10.1073/pnas.0711741105
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
J. Tsai (2008)
a novel strategy for the treatment of melanoma and other malignancies
S. J. O’Day (2007)
negative regulator of the immune response and a target for cancer therapy
Keilholz (2008)
10.1038/nature10539
A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma
C. Bertolotto (2011)
Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells.
Z. Su (2003)
10.1084/JEM.193.2.233
Antigen-Specific Inhibition of Effector T Cell Function in Humans after Injection of Immature Dendritic Cells
M. Dhodapkar (2001)
Expression of transforming growth factor-beta 2 in malignant melanoma correlates with the depth of tumor invasion. Implications for tumor progression.
J. Reed (1994)
10.1158/0008-5472.CAN-10-2954
PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression.
K. Paraiso (2011)
10.1016/S0923-1811(98)83846-2
Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization.
B. Bastian (1998)
10.1200/jco.2009.27.15_suppl.3513
A phase I study of XL281, a selective oral RAF kinase inhibitor, in patients (Pts) with advanced solid tumors.
G. Schwartz (2009)
10.1200/JCO.2004.22.14_SUPPL.4501
Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT).
M. Ratain (2004)
10.1056/NEJMoa1002011
Inhibition of mutated, activated BRAF in metastatic melanoma.
K. Flaherty (2010)
10.1038/ng1634
The melanocyte differentiation program predisposes to metastasis after neoplastic transformation
P. Gupta (2005)
10.1038/sj.onc.1207785
B-RAF is a therapeutic target in melanoma
M. Karasarides (2004)
10.1038/sj.leu.2402436
Peptide-Based Cancer Vaccines
RK Bright (2002)
10.1073/PNAS.90.8.3539
Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.
G. Dranoff (1993)
10.1016/j.cub.2005.01.031
BRAF Mutations Are Sufficient to Promote Nevi Formation and Cooperate with p53 in the Genesis of Melanoma
E. Patton (2005)
10.1016/J.CCR.2005.04.005
Protein farnesylation: implications for normal physiology, malignant transformation, and cancer therapy.
S. Sebti (2005)
10.1038/sj.onc.1207780
BRAF alterations are associated with complex mutational profiles in malignant melanoma
M. Daniotti (2004)
10.1158/0008-5472.CAN-04-1443
BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis
S. Wilhelm (2004)
10.1016/S0002-9440(10)64922-X
Importance of vascular phenotype by basic fibroblast growth factor, and influence of the angiogenic factors basic fibroblast growth factor/fibroblast growth factor receptor-1 and ephrin-A1/EphA2 on melanoma progression.
O. Straume (2002)
10.1158/1535-7163.MCT-08-0431
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E–mutated melanomas
K. S. Smalley (2008)
10.1038/onc.2008.362
CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations
K. S. Smalley (2009)
Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma.
P. Guldberg (1997)
10.1016/S0065-230X(08)60318-8
Peptide-binding heat shock proteins in the endoplasmic reticulum: role in immune response to cancer and in antigen presentation.
P. Srivastava (1993)
10.1200/JCO.2010.28.15_SUPPL.2503
Safety and efficacy results from the first-in-human study of the oral MEK 1/2 inhibitor GSK1120212.
J. Infante (2010)
10.1200/JCO.2000.18.1.158
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma.
M. Middleton (2000)
exploiting costimulation and target antigens for active and passive T cell immunotherapy
R. H. Vonderheide (2003)
10.1073/pnas.141226398
Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy
L. Fong (2001)
10.1158/0008-5472.CAN-05-2632
Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin.
Silvy da Rocha Dias (2005)
CHIR-265, a novel inhibitor that targets B-Raf and VEGFR, shows efficacy in a broad range of preclinical models
E. Venetsanakos (2006)
10.1016/J.CELLIMM.2004.09.004
PD-1 ligands, negative regulators for activation of naive, memory, and recently activated human CD4+ T cells.
G. Cai (2004)
10.1002/path.2798
The GIST paradigm: lessons for other kinase‐driven cancers
C. Antonescu (2011)
10.1038/sj.onc.1210252
Genomic profiling of malignant melanoma using tiling-resolution arrayCGH
G. Jönsson (2007)
10.1371/journal.pone.0002734
Oncogenic BRAF Regulates Melanoma Proliferation through the Lineage Specific Factor MITF
C. Wellbrock (2008)
10.1073/PNAS.91.9.3515
Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor.
Y. Kawakami (1994)
10.1056/NEJMoa1104621
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
C. Robert (2011)



This paper is referenced by
10.15252/embj.201593584
Eradicating tumor drug resistance at its YAP‐biomechanical roots
Francesca Zanconato (2016)
10.1684/bdc.2012.1677
[Diagnosis of brain metastases: an update in 2012].
E. Lechapt-Zalcman (2013)
10.3389/fonc.2014.00270
Adaptive Resistance to Immunotherapy Directed Against p53 Can be Overcome by Global Expression of Tumor-Antigens in Dendritic Cells
M. Humar (2014)
10.1371/journal.pone.0069593
Activation of Wnt/β-Catenin Signaling Increases Apoptosis in Melanoma Cells Treated with Trail
Z. F. Zimmerman (2013)
10.1016/j.ccell.2016.10.004
UNR/CSDE1 Drives a Post-transcriptional Program to Promote Melanoma Invasion and Metastasis.
L. Wurth (2016)
10.1007/978-1-62703-727-3_11
Current status of diagnostic and prognostic markers in melanoma.
D. Levine (2014)
10.1038/jid.2013.27
Mutations in ERBB4 may have a minor role in melanoma pathogenesis.
A. Manca (2013)
10.3390/ijms19123929
The Power of Fish Models to Elucidate Skin Cancer Pathogenesis and Impact the Discovery of New Therapeutic Opportunities
S. Sarasamma (2018)
10.1002/1878-0261.12695
BRAF inhibition curtails IFN‐gamma‐inducible PD‐L1 expression and upregulates the immunoregulatory protein galectin‐1 in melanoma cells
P. Gorniak (2020)
10.3978/j.issn.2305-5839.2015.08.06
Melanoma: oncogenic drivers and the immune system.
N. Karachaliou (2015)
Overexpression of CTHRC 1 in human melanoma promotes tumorigenesis targeted by miRNA 155
Y. Li (2017)
10.1111/rda.12965
Expression of kit ligand and insulin-like growth factor binding protein 3 during in vivo or in vitro development of ovarian follicles in sheep.
D. Srividya (2017)
10.1016/j.jprot.2020.103950
Integrated proteomic and transcriptomic analysis reveals that polymorphic shell colors vary with melanin synthesis in Bellamya purificata snail.
Songqian Huang (2020)
10.1038/s41598-017-07864-8
Detecting human melanoma cell re-differentiation following BRAF or heat shock protein 90 inhibition using photoacoustic and magnetic resonance imaging
A. Shah (2017)
10.14304/SURYA.JPR.V1N2.4
Genes and signaling pathways affecting the pathogenesis of melanoma
B. Varughese (2013)
Cell Cycle and Senescence Mutual Exclusivity Analysis of Genetic and Epigenetic Drivers in Melanoma Identi fi es a Link Between p 14 ARF and RAR b Signaling
C. Dahl (2013)
10.1172/JCI70156
WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors.
J. Anastas (2014)
10.1242/jcs.105270
Focal adhesion disassembly is regulated by a RIAM to MEK-1 pathway
G. Coló (2012)
10.1002/1878-0261.12103
Aberrant expression of kallikrein‐related peptidase 7 is correlated with human melanoma aggressiveness by stimulating cell migration and invasion
Tiphaine Delaunay (2017)
10.3892/or.2016.5340
ACY-1215 accelerates vemurafenib induced cell death of BRAF-mutant melanoma cells via induction of ER stress and inhibition of ERK activation.
Ueihuei Peng (2017)
10.1134/S0006297913110035
Malignant melanoma and melanocortin 1 receptor
A. A. Rosenkranz (2013)
10.1016/j.bmcl.2012.11.037
Overcoming acquired resistance to kinase inhibition: the cases of EGFR, ALK and BRAF.
S. Giroux (2013)
10.11606/D.9.2013.TDE-15012014-151634
Avaliação da atividade citotóxica e melanogênica do complexo de platina (II) com derivado de hidantoína em melanoma
F. Filippin (2013)
Genetic Determinants of Disease Persistence and Overt Off-Target Resistance to TKI therapy in Chronic Myeloid Leukemia
Gabriel A. Reyes (2014)
Anti-melanoma effects and mechanism of action of a herbal formula comprising Sophorae flos and Lonicerae Japonicae flos
T. Li (2017)
10.1186/1746-1596-8-87
Lack of SF3B1 R625 mutations in cutaneous melanoma
B. Schilling (2013)
10.1016/j.nano.2014.11.006
Recent advances in targeted nanoparticles drug delivery to melanoma.
J. Li (2015)
10.1016/j.ejcb.2013.12.002
Oncogenes in melanoma: an update.
M. Kunz (2014)
10.1158/1535-7163.MCT-17-0919
Targeting the Proteasome-Associated Deubiquitinating Enzyme USP14 Impairs Melanoma Cell Survival and Overcomes Resistance to MAPK-Targeting Therapies
Robin Didier (2018)
10.1371/journal.pone.0052760
Functional Profiling of Live Melanoma Samples Using a Novel Automated Platform
Adam Schayowitz (2012)
Systematic approaches to overcoming limitations of MAPK pathway inhibition in melanoma
David J. Konieczkowski (2013)
10.1038/s41598-017-18851-4
RGS7 is recurrently mutated in melanoma and promotes migration and invasion of human cancer cells
Nouar Qutob (2017)
See more
Semantic Scholar Logo Some data provided by SemanticScholar